Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

NCT00796666 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

131

Enrollment

INDUSTRY

Sponsor class

Stopped Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.

Conditions

Pulmonary Arterial Hypertension
Pulmonary Hypertension

Interventions

DRUG: Sitaxsentan
DRUG: Sitaxsentan and Sildenafil

Sponsor

Pfizer